{'fraction_non_alphanumeric': 0.026260504201680673, 'fraction_numerical': 0.0, 'mean_word_length': 5.108974358974359, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
ANTITUMOR ACTIVITY OF RU-PARA-CYMENE-μ-O-DICHLORIDE AGAINST DALTON ’ S LYMPHOMA IN VIVO AND IN VITRO

Ruthenium complexes are an object of great attention in the field of medicinal chemistry because of their selective antimetastatic properties and low systemic toxicity in comparison to cisplatin, the widely used antitumor drug. Ruthenium-para-cymene-μ-O-dichloride, a newly synthesised Ruthenium compound was used against Dalton’s lymphoma in vivo and in vitro to examine the cytotoxicity of the drug. The percentage survival of mice bearing Dalton’s lymphoma after treatment with different concentrations of Ruthenium-para-cymene-μ-O-dichloride was found to increase significantly along with increase in the life span of tumor bearing mice. The percentage survival and percentage increase in the life span of tumor bearing mice were found to be dose dependant. Similarly percentage survival of lymphoma cells in vitro was found to be dose dependent.